Q/C Technologies, Inc.
NCM: QCLSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Q/C Technologies, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get QCLS Z-Score →About Q/C Technologies, Inc.
Technology
Computer Hardware
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company also develops a silicon photonic computing architecture for AI inference. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
📊 Fundamental Analysis
Q/C Technologies, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -40.6%, which indicates that capital utilization is currently under pressure.
At a current price of $3.57, QCLS currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $2.50 - $33.60).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$28.04M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
2.15
52W High
$33.60
52W Low
$2.50
Avg Volume
1.12M
Day High
Day Low